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OBJECTIVES: Economic evaluation requires reliable esti-
mation techniques for hospital costing in multinational
trials. We have developed methods to assign costs to all
hospitalizations by multiplying country-speciﬁc cost 
estimates for a “base” diagnosis by a relative DRG weight
(U.S. DRG weight for the diagnosis in question/DRG
weight for the “base” diagnosis). Our objective was to
assess the validity of calculating country-speciﬁc cost 
estimates computed with U.S.-based DRG weights.
METHODS: Unit costs collected alongside Val-HeFT, a
multinational trial in heart failure, were used to compare
cost estimates provided by local economists with esti-
mates computed using U.S.-based DRG weights. Unit 
cost estimates for 8 diagnoses from 14 countries were
evaluated. We calculated the correlation between the cost
estimates and performed regression analysis to examine
the relationship between them.
RESULTS: When hospitalization for heart failure was
used as the “base” diagnosis, DRG-based cost estimates
were within 35% of the survey estimates for 86% of the
countries for unstable angina, 82% for acute MI, stroke,
and colon cancer. Costs were less well predicted for pul-
monary embolism, coronary stenting, PTCA, and heart
transplant, where only 61.5%, 54.5%, 33.3% and
30.0% of predicted costs were within 35% of survey 
estimates. The DRG-based estimates appeared to over-
estimate costs for procedure-based diagnoses as the costs
were overestimated by 40.3% for stenting, 34.9% for
PTCA, and 77.8% for heart transplant. The Pearson cor-
relation coefﬁcient between the two sets of estimates was
0.682. When excluding heart failure, the regression of
DRG-derived costs on survey-derived costs indicated that
the DRG-based methodology predicted cost estimates
fairly well (adj-R2 = 0.44) (adj-R2 = 0.571 when adjust-
ing for country).
CONCLUSIONS: Estimation of hospital costs based on
U.S. DRG weights appears to be a reasonable solution 
to costing problems in the multinational trial setting.
However, care is required in applying this technique in
studies with high frequencies of surgical procedures.
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THE RELATIONSHIP BETWEEN DISEASE AREA
AND TYPE OF ECONOMIC STUDY—DOES IT
EXIST?
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Pharmacoeconomic analysis aims to identify and measure
all costs and all outcomes associated with providing a
pharmaceutical product or service. In order to accomplish
this several economic study techniques have been used 
in the pharmacoeconomic literature in various disease
areas.
OBJECTIVES: To determine if there is a relationship
between the type of study (e.g. cost-effectiveness (CEA),
cost-beneﬁt (CBA), cost-minimisation (CMA), cost-utility
analysis (CUA)) used in a pharmacoeconomic analysis
and the disease area being investigated.
METHODS: Five disease areas, as categorised by the
British National Formulary 1 were investigated. A broad
literature search, using MESH terms, was performed
using Medline (PubMed) and abstracts that included full
and partial pharmacoeconomic analyses, from 1966 until
the present day, were considered for review.
RESULTS: 119 abstracts were. No cost-beneﬁt analyses
were found and the most commonly used full economic
techniques were cost-effectiveness and cost-utility analy-
sis; whilst cost analysis was the most commonly used
partial analytic technique. CEA was the preponderant
technique employed in the cardiovascular, respiratory 
and central nervous system disease areas, with contri-
butions of 50% (24/48), 43.48% (10/28) and 45.45%
(5/11) respectively. CUA was preponderant in the
endocrinal disease area, 30.77% (4/13), whilst CEA and
CUA were equally employed in the area of gastrointesti-
nal disease, 33.33% (8/24) and 25.00% (6/24) respec-
tively. Cost-analysis did not dominate any disease area,
and was not found to be preponderant in any speciﬁc
disease area.
CONCLUSION: Although this initial review found that
CEA was the preponderant technique employed in the
cardiovascular, respiratory and central nervous system
disease areas and CUA in the endocrinal disease area, the
relatively small number of papers reviewed cannot allow
one to draw conclusions regarding deﬁnite relation-
ships between disease areas and the type of studies used.
Further analysis of the pharmacoeconomic literature is
required to investigate possible relationships further and
highlight these where they occur.
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OBJECTIVES: To explore the use of sub-group analysis
in economic evaluation and to compare the relevance 
of such analyses to the standard recommendations for
approaching sub-group analysis in clinical studies.
METHODS: The standard pitfalls associated with ad hoc
sub group analyses in clinical evaluation are well known,
and such analyses are generally discouraged. However, in
economics, small differences in effect between sub-groups
can lead to important differences in cost-effectiveness 
for those groups. This suggests that sub-group analysis is
of critical importance for economic evaluation and the
policy decision that such evaluations seek to inform.
However, we must remain mindful of the potential pit-
falls in terms of inappropriate inference, especially when
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studies were not powered to detect sub-group differences.
We explore the use of empirical Bayes methods for esti-
mating sub-group effects while “shrinking” estimates to
account for the greater expected variance associated with
dividing the data. Two example data sets are employed:
(i) an economic evaluation of an Assertive Community
Treatment programme of mentally ill and homeless
persons in Baltimore, USA was analysed by age, race and
clinical sub-groups; and (ii) a multinational clinical trial
of drug therapy for severe heart failure was analysed by
country-speciﬁc sub-groups.
RESULTS: We demonstrate the use of shrinkage estima-
tors in these two examples and show how they lead to
cost-effectiveness estimates for sub-groups that are pulled
toward the overall estimate of cost-effectiveness for the
study. In particular, we show how small sub-groups are
adjusted to a greater extent than larger sub-groups and
we argue that this is appropriate if spurious results are to
be avoided.
CONCLUSIONS: We believe that empirical Bayes or
“shrinkage” estimators provide a potential solution to the
problem that heterogeneity in cost-effectiveness studies is
of prime importance while studies are often under-
powered with respect to potential sub-group analysis.
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OBJECTIVES: To estimate the number of life years lost
due to CHD in Germany. This approach can help to
ascribe importance to effective CHD-prevention.
METHODS: A Markov model following a cohort of
persons at age 30 was used to calculate the number of life
years lost due to CHD. In this model persons currently
developing CHD or experience a sudden cardiac death
now make a transition to a state called “eliminated
CHD”. This construction allows for a poorer survival in
the latter group, which can be attributed to positive cor-
relation between various diseases such as CHD, hyper-
tension and diabetes. Future age-speciﬁc incidence rates
were either based on a combination of risk factor distri-
bution and Framingham risk-equations or on estimations
derived at by ﬁxing future percentages of individuals
dying from CHD.
RESULTS: If CHD could be completely eliminated men
would live between 2.4 and 4.6 years longer and life
expectancy for women would increase by 1.6 to 1.7 years.
Roughly 15% of these life years are lost before the age
of 65. Most sensitive parameters were the incidence rates
and the fatality rates at the ﬁrst CHD-event. The prog-
nosis of those individuals for which the event was pre-
vented also plays an important role: If mortality in this
group is increased by 50%, life years lost fall by one third.
The long-term prognosis of CHD-cases however is com-
parably insensitive.
CONCLUSIONS: CHD is a disease, which has a large
impact on life expectancy especially for men. However
gender differences can only be partly explained by differ-
ences in CHD incidence and CHD mortality. The analy-
sis also shows the effect of inter-disease correlation on the
number of life years lost to CHD.
PMI12
DEVELOPMENT OF A NUTRITION QUALITY OF
LIFE MEASURE
Schumacher G, Barr J
Northeastern University, Boston, MA, USA
OBJECTIVES: We developed a nutrition quality of life
survey (NQOL) to (1) assist clinicians to measure/
monitor/manage the impact of dietary changes on
patients and (2) provide a patient voice in the assessment
process.
METHOD: In Stage 1, we conducted 10 patient and 7
clinician focus in 6 geographically diverse US cities to
identify physical, psychological, and social factors affect-
ing NQOL following recommended dietary modiﬁca-
tions. Each session was transcribed and read by the
investigators and three content consultants. In stage 2, 
we developed a 47-item survey, written at the 5th-6th
grade level, that included 6 item clusters: food impact, 
self image, self efﬁcacy, psychological, interpersonal, and
physical. In stage 3, we mailed the draft survey instru-
ment to each focus group participants, asking the patients
to complete the survey and asking both patients and clin-
icians to suggest improvements.
RESULTS: The 65 patients in the focus groups of stage 1
were 72/28% female/male; age range 18–>65 years;
25/63/12% low/middle/high income; 66/22/11/1% Cau-
casian/African-American/Hispanic/other; and included 7
medical conditions that led to seeking MNT. The 46 clin-
icians in the focus groups were from outpatient, inpatient,
military, public health, and home care practice sites.
Thirty-seven patients, responding to the survey in stage
3, averaged 9 minutes to complete the instrument. Only
one of the 47 items had more than two missing responses.
Based on stage 3 patient and clinician responses, the
survey was modiﬁed to add 4 questions, and improve
syntax and question order. A color format for visually
scoring the survey was also developed.
CONCLUSION: Version 1 of the NQOL is well accepted
by patients and clinicians who participated in focus
groups and responded to the draft survey and provides a
patient-based assessment of the impact of dietary modiﬁ-
cation. Further work will involve psychometric analyses
based on larger population testing, and validity/reliabil-
ity studies.
